• 1
    Lockshin MD. Therapy for systemic lupus erythematosus. N Engl J Med 1991; 324: 18991.
  • 2
    Liang MH, Corzillius M, Bae SC, Fortin P, Esdaile JN, Abrahamowicz M. A conceptual framework for clinical trials in SLE and other multisystem diseases. Lupus 1999; 8: 111.
  • 3
    Liang MH. Toward more informative pilot studies with new anti-rheumatic drugs. Agents Actions Suppl 1993; 44: 7781.
  • 4
    Liang MH, Fortin PR. Response criteria for clinical trials in systemic lupus erythematosus [published erratum appears in Lupus 1997;6:619]. Lupus 1995; 4: 3368.
  • 5
    Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999; 26: 5047.
  • 6
    Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum 2004; 50: 342731.
  • 7
    Euler HH, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe lupus erythematosus: an interim report of the Lupus Plasmapheresis Study Group. Ann Intern Med 1994: 145: 296302.
  • 8
    Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al, and The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992; 10: 54954.
  • 9
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM 1993; 86: 44758.
  • 10
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 11
    Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 110718.
  • 12
    Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of Systemic Lupus Activity Measure-Revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001; 10: 4059.
  • 13
    Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 68591.
  • 14
    Petri M, Barr SG, Buyon J, Davis J, Ginzler E, Kalunian K, et al. RIFLE: Responder Index for Lupus Erythematosus [abstract]. Arthritis Rheum 2000; 43: S244.
  • 15
    Alarcon GS, McGwin G Jr, Brooks K, Roseman JM, Fessler BJ, Sanchez ML, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores. Arthritis Rheum 2002; 47: 40813.
  • 16
    Yen JC, Neville C, Fortin PR. Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus 1999; 8: 66070.
  • 17
    Liang MH, Lew RA, Stucki G, Fortin PR, Daltroy L. Measuring clinically important changes with patient-oriented questionnaires. Med Care 2002; 40 Suppl 4: II4551.
  • 18
    Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and physician's decision to start treatment in active systemic lupus erythematosus. J Rheumatol 1998; 25: 27784.
  • 19
    Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276: 6379.
  • 20
    Fortin PR, Abrahamowicz M, Clarke AE, Neville C, DuBerger R, Fraenkel L, et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000; 27: 14218.
  • 21
    Ramsay JD, Abrahamowicz M. Binomial regression with monotone splines: a psychometric application. J Am Stat Assoc 1989; 84: 90615.
  • 22
    Abrahamowicz M, Ramsay J. Multicategorical spline model for item response theory. Psychometrika 1992; 57: 527.
  • 23
    Hastie TJ, Tibshirani RJ. Generalized additive models. London: Chapman & Hall, 1990.
  • 24
    Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Statistician 1983; 37: 3648.